secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-256326
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q3 revenue $143.8M (+32% YoY); raises FY2025 guidance to $595-605M
------------------------------------------------------------------------------

- Revenue $143.8M, up 32% vs Q3 2024; net income $24.3M ($0.66 diluted EPS) vs $4.2M a year ago.
- Gross margin improved to 59% from 56%; cash balance $466.2M as of Sept 30.
- FY2025 revenue guidance raised to $595-605M (midpoint $600M, 36% growth); prior range was $585-605M.
- Announced strategic collaboration with Mercedes-Benz to deploy V-Class vehicles for organ transport in Italy.
- Owned 21 aircraft as of Sept 30 (22 as of Oct 29); OCS growth driven by NOP and aviation fleet expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000119312525256326/0001193125-25-256326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000119312525256326/tmdx-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer